



**For Immediate Release
August 11, 2014**

**SUNSHINE BIOPHARMA'S WHOLLY OWNED CANADIAN SUBSIDIARY SECURES
DEDICATED SPACE TO COMMENCE GLOBAL GENERIC PHARMACEUTICAL
OPERATIONS**

Montreal, Quebec, Canada -- (MARKETWIRE) -- Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its wholly owned Canadian subsidiary has secured dedicated space in order to commence operations in the generic pharmaceuticals business as planned. Having a specifically dedicated space is required in order for the Company to be granted a Pharmaceutical Establishment and Export License by Health Canada. Once we secure our Establishment License we will be in a position to sign manufacturing and distribution contracts for sale of generic pharmaceuticals in Canada and elsewhere around the globe. According to various estimates, the annual worldwide market for generic pharmaceuticals which Sunshine Biopharma's Canadian subsidiary is positioning itself to participate in is in excess of \$100 billion.

"This new effort broadens our business scope and provides us with the opportunity to generate revenues in the near to mid-term," said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. "Any attendant profits from such operations will be used to fund our proprietary drug development program including Adva-27a, our flagship oncology drug candidate currently being developed for the treatment of Pancreatic Cancer and Multidrug Resistant Breast Cancer. This revenue generation endeavor is very important as it makes us less dependent on capital markets for financing of our operations."

About Adva-27a

Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing Multidrug Resistant Breast Cancer cells, Small-Cell Lung Cancer cells, Uterine Sarcoma cells and Pancreatic Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935. The Company is planning a Phase I clinical trial of Adva-27a for Pancreatic Cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant Breast Cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information Contact:

Camille Sebaaly, CFO

Sunshine Biopharma Inc.

Direct Line: 514-814-0464

camille.sebaaly@sunshinebiopharma.com

www.sunshinebiopharma.com